Abstracts tagged "Mixed connective tissue disease (MCTD)"

Abstract Number: 035 • 2020 Pediatric Rheumatology Symposium
The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort
Stacy Ardoin¹, Stephen Balevic ², Aimee Hersh ³, Yukiko Kimura ⁴, Andrea Knight ⁵, Laura Schanberg ⁶, Mary Beth Son ⁷ and Timothy Beukelman ⁸ for the CARRA investigators, ¹Nationwide Children's Hospital, Columbus, ²Duke University, Hillsborough, ³University of Utah Primary Children's Hospital, Salt Lake City, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵SickKids Research Institute, Toronto, Canada, ⁶Duke Children's Hospital & Health Center, Durham, North Carolina, ⁷Boston Children's Hospital, Boston, Massachusetts, ⁸University of Alabama at Birmingham, Birmingham
Background/Purpose: Optimal therapy in childhood onset systemic lupus erythematosus (SLE) lack sufficient data to support clinical decision making. To address this knowledge gap, the Childhood…
Abstract Number: 056 • 2020 Pediatric Rheumatology Symposium
Non-criteria Antiphospholipid Antibodies Associated with Pediatric Rheumatic Disease: A Single-Center Case Series
Shawn Mahmud¹, Danielle Bullock ¹, Colleen Correll ¹, Patricia Hobday ², Mona Riskalla ³, Richard Vehe ⁴ and Bryce Binstadt ¹, ¹University of Minnesota, Minneapolis, ²Minneapolis, ³University of Minnesota, Minneapolis, Minnesota, ⁴University of Minnesota, Roseville
Background/Purpose: Non-criteria antiphospholipid antibodies (NC-aPL) bind molecules such as phosphatidylethanolamine (PE), phosphatidylserine (PS), and prothrombin (Pt), but not the targets of routine antiphospholipid (aPL) testing…
Abstract Number: 2413 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Mixed Connective Tissue Disease: Results from a Multicentre Cohort Study
Massimo Radin¹, Karen Schreiber², Maria Jose Cuadrado³, Irene Cecchi⁴, Laura Andreoli⁵, Franco Franceschini⁶, Maria Teresa Caleiro⁷, Danieli Andrade⁸, Elena Gibbone⁹, Munther A Khamashta¹⁰, Jill P. Buyon¹¹, Peter M. Izmirly¹², Maria Aguirre¹³, Chiara Benedetto⁹, Dario Roccatello¹⁴, Luca Marozio¹⁵ and Savino Sciascia¹⁶, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ³Clinica Universidad de Navarra, Madrid, Spain, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ⁷Rheumatology, University of São Paulo, Tucson, AZ, ⁸Rheumatology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁹University of Turin, Turin, Italy, ¹⁰Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ¹¹Medicine, New York University School of Medicine, New York, NY, ¹²NYU Langone Health, New York, NY, ¹³IMIBIC, Cordoba, Cordoba, Spain, ¹⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ¹⁵University of Turin, Torino, Italy, ¹⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Mixed connective tissue disease (MCTD) is characterized by signs and symptoms of a combination of disorders, primarily systemic lupus erythematosus (SLE), scleroderma and polymyositis…
Abstract Number: 2698 • 2018 ACR/ARHP Annual Meeting
Renal Involvement in Mixed Connective Tissue Disease: A Single Center Experience
Eduardo Martín Nares¹, Silvia Eunice Ramírez Andrade², Luis Eduardo Morales Buenrostro², Norma Ofelia Uribe Uribe³, Laura R Cárdenas M³, Montserrat Reyes Macedo³ and Tatiana S. Rodriguez-Reyna¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Kidney injury in mixed connective tissue disease (MCTD) is an uncommon manifestation. Prevalence has been reported to be <4% in some cohorts. The frequency…
Abstract Number: 339 • 2017 ACR/ARHP Annual Meeting
Patients’ Attitudes and Experiences of Transitional Care in Paediatric Rheumatology: A Systematic Review of Qualitative Studies
Ayano Kelly^1,2,3,4, Fiona Niddrie⁵, David Tunnicliffe^4,6, Camilla Hanson^4,7, Gabor Major^8,9, Davinder Singh-Grewal^10,11,12 and Allison Tong⁴, ¹Rheumatology, The Canberra Hospital, Canberra, Australia, ²School of Medicine, Australian National University, Canberra, Australia, ³Canberra Rheumatology, Canberra, Australia, ⁴Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia, ⁵Rheumatology, Bone and Joint Institute,John Hunter Hospital, Newcatle, Australia, ⁶Sydney School of Public Health, University of Sydney, Sydney, Australia, ⁷Sydney School of Pubic Health, University of Sydney, Sydney, Australia, ⁸Medicine, University of Newcastle, Newcastle, Australia, ⁹Rheumatology, Bone and Joint Institute, John Hunter Hospital NSW Australia, Newcastle, Australia, ¹⁰Faculty of Medicine, University of New South Wales, Sydney, Australia, ¹¹Department of Rheumatology, The Sydney Children's Hospital Network, Sydney, Australia, ¹²Sydney Medical School, University of Sydney, Sydney, Australia
Background/Purpose: Despite the increasing number of transition programs available for rheumatology patients moving from paediatric to adult care, transition continues to pose challenges for patients…
Abstract Number: 1639 • 2017 ACR/ARHP Annual Meeting
Longitudinal Evolution in a Nationwide Cohort Originally Classified As Mixed Connective Tissue Disease
Silje Reiseter¹, Ragnar Gunnarsson², Jukka Corander³, Johanna Haydon⁴, May Brit Lund⁵ and Øyvind Molberg¹, ¹Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, OSLO, Norway, ³Departement of Biostatistics, University of Oslo, Oslo, Norway, ⁴Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁵Respiratory Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Ever since Mixed Connective Tissue Disease was presented as a distinct entity in 1972, it has been discussed whether MCTD represents an undifferentiated, transient…
Abstract Number: 2094 • 2017 ACR/ARHP Annual Meeting
Prevalence of Organ Involvement in Mixed Connective Tissue Disease
Javier Narváez¹, Maria Pascual², Gloria Albert Espi³, Milena Millan⁴, Mercè López de Recalde⁵, Juan José Alegre⁶, Ivan Castellví⁷, Carmen Gomez Vaquero⁵ and Joan Miquel Nolla⁸, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ³Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Rheumatology, Hospital de Sant Pau, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Sección de Reumatología Hospital Universitario Dr Peset Valencia, Valencia, Spain, ⁷Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: : Mixed connective tissue disease (MCTD) is characterized by overlapping features of SLE, SSc, PM/DM and rheumatoid arthritis together with the presence of high-titre…
Abstract Number: 409 • 2015 ACR/ARHP Annual Meeting
Disease Activity, Disease Damage and Predictive Factors in Juvenile Onset Mixed Connective Tissue Disease – a Norwegian Nationwide Study
Siri Opsahl Hetlevik¹, Berit Flatø^1,2, Marite Rygg^3,4, Ellen Berit Nordal⁵ and Vibke Lilleby⁶, ¹Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, ³Department of Pediatrics, St Olav University Hospital, Trondheim, Norway, ⁴Department of Laboratory Medicine, Children's and Women's health, Norwegian University of Science and Technology, Trondheim, Norway, ⁵Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ⁶Rheumatology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Mixed Connective Tissue Disease (MCTD) is a rare rheumatic disease with overlapping features from Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Polymyositis. Juvenile…
Abstract Number: 1263 • 2015 ACR/ARHP Annual Meeting
Applications of Protein Microarray for Saliva Diagnostics in Autoimmune Diseases
Yeon-Ah Lee¹, Yong-Gil Kim², Seung-Jae Hong¹ and Paul J. Utz³, ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kyung Hee University, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: There have been many reports showing that saliva could be a source of biomarkers capable of detecting certain diseases. However, very few studies have…
Abstract Number: 1299 • 2014 ACR/ARHP Annual Meeting
A Cross-Sectional Study of Mental Health Symptoms and Mental Health Care in Pediatric SLE/MCTD Patients and Their Peers
Andrea Knight^1,2, Michelle Vickery¹, Pamela Weiss^1,2,3, Knashawn Morales³ and Ron Keren^3,4, ¹Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ²Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Mental health problems are prevalent in pediatric systemic lupus erythematosus (SLE). We aimed to compare the rates of mental health problems and mental health…
Abstract Number: 2703 • 2014 ACR/ARHP Annual Meeting
Elevated Serum Levels of Endostatin in Mixed Connective Tissue Disease – Association with Pulmonary Fibrosis and Digital Ulcers
Silje Reiseter¹, Ragnar Gunnarsson², Torhild Garen², May Brit Lund³, T. Mogens Aalokken⁴, Anna-Maria Hoffmann-Vold⁵, Øyvind Molberg^2,6 and Thor Ueland⁷, ¹Department of Rheumatology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Department of Respiratory Medicine, Oslo University Hospital Rikshopitalet, Oslo, Norway, ⁴Department of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁵Department of Rheumatology, Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁶Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ⁷Research Institute for Internal Medicine, University of Oslo, Oslo, Norway
Background/Purpose Mixed Connective Tissue Disease (MCTD) is a chronic, immune-mediated disorder defined by the combined presence of serum anti-RNP antibodies and selected clinical features of…
Abstract Number: 2588 • 2013 ACR/ARHP Annual Meeting
Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies
Vincent Sobanski¹, Bernadette Lynch², Benjamin E. Schreiber³, Svetlana I. Nihtyanova⁴, Jennifer Harvey⁵, Clive Handler⁶, Christopher P. Denton⁷ and John G. Coghlan⁸, ¹Department of Rheumatology, Royal Free Hospital, London, United Kingdom, ²Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ³Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ⁴Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁵Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁶Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, ⁷Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁸National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of morbidity and mortality in patients with connective tissue diseases (CTD). Patients with anti-U1-RNP antibodies belong to…
Abstract Number: 2034 • 2013 ACR/ARHP Annual Meeting
Does Mixed Connective Tissue Disease Or Sharp’s Syndrome Really Exist?
Anne Barbarini¹, Christelle Sordet¹, Emmanuel Chatelus¹, Rose-Marie Javier¹, Joelle Goetz², Francois Lefebvre³, Jacques-Eric Gottenberg⁴, Thierry Martin⁵ and Jean Sibilia⁴, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²rheumatology, Strasbourg University Hospital, Strasbourg, France, ³Strasbourg University Hospital, strasbourg, France, ⁴Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁵Strasbourg University Hospital, Strasbourg, France
Background/Purpose: The existence of Mixed Connective Tissue Disease (MCTD) has often been discussed in literature and its diagnostic criteria are very heterogeneous. Anti-U1-RNP antibodies are…
Abstract Number: 1928 • 2012 ACR/ARHP Annual Meeting
Evaluating the Therapeutic Effects of B Cell Depletion Therapy with Rituximab in a Longitudinal Cohort of Mixed Connective Tissue Disease Patients
Ragnar Gunnarsson¹, Inge-Margrethe Gilboe¹, Torhild Garen² and Øyvind Molberg³, ¹Rheumatology unit, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway
Background/Purpose: Even though 40 years have passed since MCTD was defined as a distinct disorder, there is still no evidence based therapy available. The choice…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.